{
    "title": "Pfizer boosts 2022 COVID vaccine forecast, looks to pivot with deals, new drugs",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11377051/Pfizer-raises-sales-estimates-COVID-vaccine-2-billion.html",
    "date": "2022-11-01",
    "keywords": [
        "vaccine",
        "pfizer",
        "company",
        "pipeline",
        "inc",
        "patent",
        "covid19",
        "development",
        "revenue",
        "thirdquarter",
        "beat",
        "covid",
        "growth",
        "companys",
        "erman",
        "tuesday",
        "forecast",
        "profit",
        "partner",
        "pfizerbiontech",
        "end",
        "vaccination",
        "demand",
        "booster",
        "response",
        "price",
        "government",
        "shift",
        "market",
        "executive",
        "albert",
        "bourla",
        "interview",
        "crisis",
        "business",
        "loss",
        "acquisition",
        "blood",
        "purchase",
        "biohaven",
        "colitis",
        "virus",
        "rsv",
        "latestage",
        "study",
        "capital",
        "analyst",
        "seigerman",
        "towel",
        "balance",
        "sheet",
        "flexibility",
        "paxlovid",
        "treatment",
        "share",
        "quarter",
        "bengaluru",
        "editing",
        "dasgupta",
        "sriraj",
        "kalluvila",
        "bill",
        "berkrot"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}